RAPT Share Price | Rapt Therapeutics, Inc. Stock Analysis & Recommendation

Q: How big is Rapt Therapeutics, Inc.?

Market Cap: As of Jun 18, Rapt Therapeutics, Inc. has a market capitalization of 129.64 million, categorizing it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters, Rapt Therapeutics, Inc. reported net sales of 0.00 million and a net profit of -116.50 million.Balance Sheet Snapshot: As of December 2024, the company reported shareholder's funds of 189.90 million and total assets of 240.32 million.

Q: What does Rapt Therapeutics, Inc. do?

Overview: Rapt Therapeutics, Inc. is a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases, operating within the Pharmaceuticals & Biotechnology industry and categorized as a micro-cap company.Financial Snapshot: Most recent Net Profit: -17 Million (Quarterly Results - Mar 2025) Market cap: USD 129.64 Million (Micro Cap) Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -1.00 Return on Equity: -65.69% Price to Book: 0.73 Contact Details: Address: 561 Eccles Ave, SOUTH SAN FRANCISCO CA: 94080-1906 Tel: 1 650 4899000 Website: https://www.rapt.com/

Q: Who are in the management team of Rapt Therapeutics, Inc.?

As of March 2022, the management team of Rapt Therapeutics, Inc. includes Dr. Brian Wong, who serves as the President, Chief Executive Officer, and Director. Additionally, the Board of Directors features Mr. Peter Svennilson, Dr. Michael Giordano, Dr. Mary Gray, Linda Kozick, and Mr. William Rieflin, all of whom hold independent director positions.

Q: Is Rapt Therapeutics, Inc. overvalued or undervalued?

As of 11 May 2023, the valuation grade for Rapt Therapeutics, Inc. has moved from risky to does not qualify, indicating a significant deterioration in its financial standing. The company is currently considered overvalued, given its negative performance metrics, including a P/E ratio that is not applicable due to losses, a Price to Book Value of 0.87, and an EV to EBITDA ratio of 0.19. Additionally, the Return on Equity (ROE) stands at a concerning -65.69%, highlighting ongoing financial struggles.In comparison to its peers, Rapt Therapeutics, Inc. shows a stark contrast to Tarsus Pharmaceuticals, Inc., which has a P/E ratio of -16.08 and an EV to EBITDA of -12.26, and Viridian Therapeutics, Inc. with a P/E of -4.13 and an EV to EBITDA of -1.77. This suggests that Rapt's valuation does not align favorably within its industry context. Despite a remarkable recent stock performance, with a one-week return of 622.33% compared to a slight decline in the S&P 500, the underlying financial ratios indicate that the stock is not justified at its current price of 7.44.

Q: Is Rapt Therapeutics, Inc. technically bullish or bearish?

As of 4 September 2025, the technical trend for Rapt Therapeutics, Inc. has changed from mildly bullish to bullish. The current stance is bullish with strong indicators supporting this view. The weekly MACD is bullish, and the daily moving averages also confirm a bullish trend. The KST is bullish on a weekly basis, and the On-Balance Volume (OBV) is bullish for both weekly and monthly periods. However, the Bollinger Bands show a mildly bearish signal on the monthly timeframe, indicating some caution.In terms of performance, Rapt Therapeutics has significantly outperformed the S&P 500 over the past week (30.57% vs. 1.05%) and month (74.77% vs. 2.33%), while the year-to-date return of 62.18% also surpasses the S&P's 12.22%. Overall, the technical indicators suggest a strong bullish sentiment, despite some mixed signals in the longer-term trends.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

11.02 M

Shareholding (Sep 2025)

FII

21.40%

Held by 61 FIIs

DII

7.62%

Held by 16 DIIs

Promoter

57.57%

How big is Rapt Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Rapt Therapeutics, Inc. has a market capitalization of 129.64 million, with net sales of 0.00 million and a net profit of -116.50 million over the latest four quarters. As of December 2024, the company reported shareholder's funds of 189.90 million and total assets of 240.32 million.

View full answer

What does Rapt Therapeutics, Inc. do?

22-Jun-2025

Rapt Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing oral small molecule therapies for oncology and inflammatory diseases. It has a market cap of $129.64 million and reported a net profit loss of $17 million as of March 2025.

View full answer

Who are in the management team of Rapt Therapeutics, Inc.?

22-Jun-2025

As of March 2022, Rapt Therapeutics, Inc.'s management team includes Dr. Brian Wong as President and CEO, with independent directors Mr. Peter Svennilson, Dr. Michael Giordano, Dr. Mary Gray, Linda Kozick, and Mr. William Rieflin on the Board.

View full answer

Is Rapt Therapeutics, Inc. overvalued or undervalued?

25-Jun-2025

As of May 11, 2023, Rapt Therapeutics, Inc. is considered overvalued with a valuation grade of "does not qualify" due to negative financial metrics, including a P/E ratio not applicable from losses, a Price to Book Value of 0.87, an EV to EBITDA of 0.19, and a troubling ROE of -65.69%, despite a recent stock surge of 622.33%.

View full answer

Is Rapt Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of September 4, 2025, Rapt Therapeutics, Inc. shows a bullish trend with strong indicators, outperforming the S&P 500 significantly, although caution is advised due to a mildly bearish signal from the Bollinger Bands on the monthly timeframe.

View full answer

Compare Rapt Therapeutics, Inc. with Similar Stocks

Tarsus Pharmaceuticals, Inc.Phathom Pharmaceuticals, Inc.Kiniksa Pharmaceuticals Ltd.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 1,596 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.02

Return on Equity

-69.51%

Price to Book

10.50

Revenue and Profits:

Net Sales:

(Quarterly Results - Sep 2025)

Net Profit:

-18 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

102.39%

6 Months

436.06%

1 Year

549.55%

2 Years

-71.07%

3 Years

105.63%

4 Years

-63.51%

5 Years

-65.19%

Rapt Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-100.00%

EBIT Growth (5y)

-179.74%

EBIT to Interest (avg)

-95.52

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.00

Sales to Capital Employed (avg)

0.00

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

0.87

EV to EBIT

0.18

EV to EBITDA

0.19

EV to Capital Employed

-22.18

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-65.69%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

Mildly Bullish

RSI

Bearish

Bollinger Bands

Mildly Bullish

Moving Averages

Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

Mildly Bullish

OBV

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Majority shareholders

Strategic Entities

Domestic Funds

Held in 39 Schemes (13.39%)

Foreign Institutions

Held by 61 Foreign Institutions (21.4%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Jun 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Sep 2025 is 0.00% vs -2.33% in Jun 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Jun'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-19.20",
          "val2": "-19.30",
          "chgp": "0.52%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-17.60",
          "val2": "-17.60",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs -100.00% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -11.22% vs -39.38% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-132.60",
          "val2": "-123.50",
          "chgp": "-7.37%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-129.90",
          "val2": "-116.80",
          "chgp": "-11.22%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ

Sep'25

Jun'25

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-19.20

-19.30

0.52%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-17.60

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Jun 2025

Consolidated Net Profit

QoQ Growth in quarter ended Sep 2025 is 0.00% vs -2.33% in Jun 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-132.60

-123.50

-7.37%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-129.90

-116.80

-11.22%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs -100.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -11.22% vs -39.38% in Dec 2023

All Annual Results

Company CV

About Rapt Therapeutics, Inc.

Rapt Therapeutics, Inc.

Pharmaceuticals & Biotechnology

RAPT Therapeutics, Inc. is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. It is developing selective small molecules designed to modulate the critical immune responses underlying these diseases. It has discovered and advanced two drug candidates FLX475 and RPT193, which is engaged in targeting C-C motif chemokine receptor 4 (CCR4). Its drug discovery and development engine has identified CCR4 as a drug target that potentially has broad applicability in oncology and inflammatory diseases. Its lead oncology drug candidate FLX475, is designed to selectively inhibit the migration of immunosuppressive regulatory Treg cells into tumors. Its RPT193 drug candidate, is designed to selectively inhibit the migration of type 2 T helper cells (Th2 cells), into allergically-inflamed tissues.

Company Coordinates

Company Details

561 Eccles Ave , SOUTH SAN FRANCISCO CA : 94080-1906

Tel: 1 650 4899000

https://www.rapt.com/

Registrar Details

Rapt Therapeutics, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Rapt Therapeutics, Inc.?

Watch in Real-Time

What does Rapt Therapeutics, Inc. do?

Who are in the management team of Rapt Therapeutics, Inc.?

Is Rapt Therapeutics, Inc. overvalued or undervalued?

Is Rapt Therapeutics, Inc. technically bullish or bearish?

Compare Rapt Therapeutics, Inc. with Similar Stocks

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ

Annual Results Snapshot (Consolidated) - Dec'24

About Rapt Therapeutics, Inc.

Company Coordinates